Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

被引：37

作者：

Ozeki, Michio ^{[1
]}

Nozawa, Akifumi ^{[1
]}

Kanda, Kaori ^{[1
]}

Hori, Tomohiro ^{[1
]}

Nagano, Akihito ^{[2
]}

Shimada, Akira ^{[4
]}

Miyazaki, Tatsuhiko ^{[3
]}

Fukao, Toshiyuki ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Pediat, Yanagido 1-1, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Orthoped Surg, Gifu, Japan

[3] Gifu Univ, Grad Sch Med, Dept Pathol, Gifu, Japan

[4] Okayama Univ, Dept Pediat, Grad Sch Med, Okayama, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2017年 / 39卷 / 06期

关键词：

soft tissue tumor; vascular tumor; mammalian target of rapamycin (mTOR) inhibitor; kaposiform hemangioendothelioma (KHE); phosphoinositide-3-kinase (PI3K); PLASMINOGEN-ACTIVATOR INHIBITOR-1; SARCOMA-LIKE HEMANGIOENDOTHELIOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; CANCER; SIROLIMUS; PAI-1;

D O I：

10.1097/MPH.0000000000000778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

引用

页码：E328 / E331

页数：4

共 50 条

[31] Dermoscopic findings of pseudomyogenic hemangioendothelioma: a case report
Wang, Xiaofang
Fei, Wenmin
Wu, Hongxuan
Wan, Chuan
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (07) : 900 - 903
[32] Pseudomyogenic Hemangioendothelioma of the Talocalcaneal Coalition: A Case Report
Xu, Zhijie
Zaid, Hamood H. G.
Yang, Maowei
JOURNAL OF FOOT & ANKLE SURGERY, 2021, 60 (05): : 1073 - 1078
[33] FOSB Is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma
Hung, Yin
Fletcher, Christopher D. M.
Hornick, Jason L.
MODERN PATHOLOGY, 2017, 30 : 16A - 16A
[34] FOSB Is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma
Hung, Yin
Fletcher, Christopher D. M.
Hornick, Jason L.
LABORATORY INVESTIGATION, 2017, 97 : 16A - 16A
[35] Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature
Raftopoulos, Emily
Royer, Michael
Warren, Mildred
Zhao, Jin
Rush, Walter
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2018, 40 (08) : 597 - 601
[36] Multifocal pseudomyogenic hemangioendothelioma of the thigh: A case report
Bai, Lin-Lin
Zhang, Ke-Xin
Liu, Li-Dan
Xu, Hong-Tao
ASIAN JOURNAL OF SURGERY, 2024, 47 (09) : 3921 - 3922
[37] Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma
van IJzendoorn, David G. P.
Sleijfer, Stefan
Gelderblom, Hans
Eskens, Ferry A. L. M.
van Leenders, Geert J. L. H.
Szuhai, Karoly
Bovee, Judith V. M. G.
CLINICAL CANCER RESEARCH, 2018, 24 (11) : 2678 - 2687
[38] Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report
Shinya Otani
Robert Nakayama
Tetsuya Sekita
Toru Hirozane
Naofumi Asano
Kazumasa Nishimoto
Aya Sasaki
Hajime Okita
Hideo Morioka
Masaya Nakamura
Morio Matsumoto
BMC Cancer, 19
[39] Pseudomyogenic Hemangioendothelioma: A Rare Vascular Tumor of the Oral Cavity
Ramos-Fuentes, Hector
Ortiz-Diaz, Cristina
Sifuentes-Cervantes, Salvador
Castro-Nunez, Jaime
JOURNAL OF CRANIOFACIAL SURGERY, 2020, 31 (04) : E333 - E334
[40] Oral Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature
Austin J. Shackelford
Carleigh R. Canterbury
Michael A. Perrino
Joseph Wang
Elizabeth M. Philipone
Scott M. Peters
Head and Neck Pathology, 2020, 14 : 1134 - 1138

← 1 2 3 4 5 →